Septerna (NASDAQ:SEPN) Now Covered by Analysts at TD Cowen

Analysts at TD Cowen began coverage on shares of Septerna (NASDAQ:SEPN) in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. The firm set a “buy” rating on the stock.

Septerna Trading Up 4.5 %

NASDAQ:SEPN opened at $23.55 on Tuesday. Septerna has a 52-week low of $18.62 and a 52-week high of $26.34.

Insider Transactions at Septerna

In other news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was bought at an average price of $18.00 per share, with a total value of $6,669,000.00. Following the acquisition, the insider now owns 6,215,591 shares of the company’s stock, valued at approximately $111,880,638. This represents a 6.34 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.